Senti Biosciences, Inc.

SNTI Healthcare Biotechnology

Senti Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $22,000.00, down 99.1% from fiscal 2023. In the quarter to June 2026, revenue fell 98.7%, EPS grew 26.8% and free cash flow fell 7.48%, each against the same quarter a year earlier.

0.22 0.04 −15.38%
Market cap
$8.1M
P/E
0.0×
Fwd P/E
−0.9×
Dividend yield
—
F-score
n/a
Altman Z
−13.71
Beneish M
n/a
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Older periods Sep '25 Dec '25 Mar '26 Jun '26
Total current assets
18.16 23.27 14.79 13.01
Total non-current assets
34.53 27.95 23.45 20.10
Total Assets
52.69 51.22 38.24 33.11
Total current liabilities
12.03 13.97 14.27 15.77
Total non-current liabilities
32.54 31.66 21.41 20.74
Total liabilities
44.56 45.63 35.68 36.51
Common Equity (Total)
8.12 5.59 2.57 (3.40)
Shareholders Equity (Total)
8.12 5.59 2.57 (3.40)

Show all line items

In millions of $ except per-share values · columns are period end dates